{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:43:24Z","timestamp":1777643004518,"version":"3.51.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To observe the real-world utilization patterns, effectiveness and safety profile of follitropin delta in women \u226518 years na\u00efve to ovarian stimulation undergoing <jats:italic>in vitro<\/jats:italic> fertilization (IVF) or intracytoplasmic sperm injection (ICSI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective, multinational, multicenter, observational study. All IVF\/ICSI treatment protocols were conducted according to routine clinical practice, including undertaking fresh\/frozen transfers. Outcomes included use of dosing algorithm, follitropin delta dosing patterns, ovarian response, pregnancy rates and adverse drug reactions (ADRs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The first ovarian stimulation cycle using follitropin delta was initiated in 944 women. Mean baseline demographics were: age, 33.5 \u00b1 4.7 years; bodyweight, 67.1 \u00b1 13.6\u00a0kg; anti-M\u00fcllerian hormone, 20.3 \u00b1 16.1 pmol\/L (2.84 \u00b1 2.25 ng\/mL). The dosing algorithm was used to calculate the follitropin delta daily starting dose in 893\/944 women (94.5%). The mean difference between the calculated and prescribed daily dose was small (0.2 \u00b1 1.40 \u00b5g). The mean daily starting follitropin delta dose was 10.4 \u00b1 2.72\u00a0\u00b5g and the mean total dose administered was 104\u00a0\u00b5g. Follitropin delta dose adjustments were reported for 57\/944 (6.0%) women. The mean number of retrieved oocytes was 10.1 \u00b1 7.03. Ongoing pregnancy at 10\u201311 weeks was reported for 255 women (27.0% per initiated cycle and 43.1% per fresh transfer [n=592]). Cumulative ongoing pregnancy rate after fresh and\/or frozen transfer was 36.4% (344\/944). Four women discontinued follitropin delta due to ADRs. Ovarian hyperstimulation syndrome (OHSS) was the most frequently reported ADR (n=37 [3.9%]); most cases of OHSS were of mild or moderate intensity (n=30 [3.2%]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This large real-world study of follitropin delta utilization patterns confirms its good pregnancy rates while minimizing OHSS risk during first ovarian stimulation cycle.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.992677","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T15:44:30Z","timestamp":1671723870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study)"],"prefix":"10.3389","volume":"13","author":[{"given":"Christophe","family":"Blockeel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Rago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yum Lina Yip","family":"Sonderegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joop S. E.","family":"Laven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2012.12.048","article-title":"Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: Prediction of ovarian response and cumulative treatment outcome in good-prognosis patients","volume":"99","author":"Arce","year":"2013","journal-title":"Fertil Steril"},{"key":"B2","unstructured":"Ovarian stimulation for IVF\/ICSIGuideline of the European society of human reproduction and embryology2019"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: From theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/bs.vh.2018.01.018","article-title":"The ovarian hyperstimulation syndrome","volume":"107","author":"Blumenfeld","year":"2018","journal-title":"Vitam Horm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","article-title":"Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection","volume":"102","author":"Arce","year":"2014","journal-title":"Fertil Steril"},{"key":"B6","article-title":"Follitropin delta Summary of Product Characteristics","volume-title":"Rekovelle 72 Microgram\/2.16 ml solution for injection in a pre-filled pen","year":""},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12864","article-title":"Follicular and endocrine dose responses according to anti-mullerian hormone levels in IVF patients treated with a novel human recombinant FSH (Fe 999049)","volume":"83","author":"Bosch","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0276-8","article-title":"Dose-exposure proportionality of a novel recombinant follicle-stimulating hormone (rFSH), Fe 999049, derived from a human cell line, with comparison between Caucasian and Japanese women after subcutaneous administration","volume":"35","author":"Olsson","year":"2015","journal-title":"Clin Drug Investig"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0129-9","article-title":"Population pharmacokinetic modelling of Fe 999049, a recombinant human follicle-stimulating hormone, in healthy women after single ascending doses","volume":"16","author":"Rose","year":"2016","journal-title":"Drugs R D"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13956","article-title":"Anti-mullerian hormone variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta","volume":"90","author":"Nelson","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil Steril"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","volume":"42","author":"Ishihara","year":"2021","journal-title":"Reprod BioMed Online"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"36","author":"Qiao","year":"2021","journal-title":"Hum Reprod"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-021-02271-5","article-title":"Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta","volume":"38","author":"Havelock","year":"2021","journal-title":"J Assist Reprod Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/jog.14626","article-title":"Retrospective analysis of the use of two recombinant follitropin Alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin-releasing hormone antagonist protocol","volume":"47","author":"\u0160prem Gold\u0161tajn","year":"2021","journal-title":"J Obstet Gynaecol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.636038","article-title":"New human follitropin preparations: How glycan structural differences may affect biochemical and biological function and clinical effect","volume":"12","author":"Dias","year":"2021","journal-title":"Front Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2018.12.032","article-title":"Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: Cumulative data over three stimulation cycles","volume":"38","author":"Fernandez-Sanchez","year":"2019","journal-title":"Reprod BioMed Online"},{"key":"B18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.rbmo.2018.10.012","article-title":"Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind phase 3 safety trial","volume":"38","author":"Bosch","year":"2019","journal-title":"Reprod BioMed Online"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.rbmo.2019.12.001","article-title":"Context-based infertility care","volume":"40","author":"Macklon","year":"2020","journal-title":"Reprod BioMed Online"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.13090","article-title":"Is it possible to apply trial outcomes to a real-world population? A novel approach to external validity analysis","volume":"60","author":"Agresta","year":"2020","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012586","article-title":"Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis","author":"Gallos","year":"2017","journal-title":"Cochrane Database Systematic Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2014-0022","article-title":"First fully automated immunoassay for anti-m\u00fcllerian hormone","volume":"52","author":"Gassner","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deac061","article-title":"A randomized, controlled, first-in-Patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol","volume":"37","author":"Fernandez Sanchez","year":"2022","journal-title":"Hum Reprod"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.12.013","article-title":"An eight centre, retrospective, clinical practice data analysis of algorithm-based treatment with follitropin delta","volume":"44","author":"Bachmann","year":"2022","journal-title":"Reprod BioMed Online"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dez184","article-title":"Individualized ovarian stimulation in IVF\/ICSI treatment: It is time to stop using high FSH doses in predicted low responders","volume":"35","author":"Leijdekkers","year":"2019","journal-title":"Hum Reprod"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.03.027","article-title":"What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders","volume":"94","author":"Berkkanoglu","year":"2010","journal-title":"Fertil Steril"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.08.048","article-title":"Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"106","year":"2016","journal-title":"Fertil Steril"},{"key":"B28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/s1472-6483(10)60042-9","article-title":"Symposium: Update on prediction and management of OHSS. A modern classification of OHSS","volume":"19","author":"Golan","year":"2009","journal-title":"Reprod BioMed Online"},{"key":"B29","unstructured":"The management of ovarian hyperstimulation syndrome2016"},{"key":"B30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3978\/j.issn.2305-5839.2015.04.09","article-title":"Comparison of different stimulation protocols used in in vitro fertilization: a review","volume":"3","author":"Shrestha","year":"2015","journal-title":"Ann Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dml038","article-title":"Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis","volume":"12","author":"Kolibianakis","year":"2006","journal-title":"Hum Reprod Update"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1472-6483(10)61059-0","article-title":"Gonadotrophin-releasing hormone antagonists for assisted conception: a cochrane review","volume":"14","author":"Al-Inany","year":"2007","journal-title":"Reprod BioMed Online"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001750.pub4","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa241","article-title":"Developing a core outcome set for future infertility research: an international consensus development study","volume":"35","author":"Duffy","year":"2020","journal-title":"Hum Reprod"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ph13070136","article-title":"Human recombinant FSH and its biosimilars: Clinical efficacy, safety, and cost-effectiveness in controlled ovarian stimulation for in vitro fertilization","volume":"13","author":"Bergandi","year":"2020","journal-title":"Pharm (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1910026","article-title":"The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature","volume":"21","author":"\u0160prem Gold\u0161tajn","year":"2021","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2022.01.011","article-title":"Originator recombinant human follitropin Alfa versus recombinant human follitropin Alfa biosimilars in Spain: a cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers","author":"Schwarze","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.992677\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T15:44:37Z","timestamp":1671723877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.992677\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":37,"alternative-id":["10.3389\/fendo.2022.992677"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.992677","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"article-number":"992677"}}